摘要
Comment on the article ‘Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes’ which was published in the New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2403347. The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study is a company-funded, randomized, double-blind, placebo-controlled, event-driven, superiority trial, assessing the efficacy and safety of the glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, on renal outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).1 Subjects were randomly assigned 1:1 to receive either subcutaneously once-weekly semaglutide (1.0 mg) or a visually identical placebo, added to standard-of-care therapy.1 A total of 3433 patients were enrolled at 387 sites across 28 countries. Eligibility criteria included a diagnosis of T2D with glycated haemoglobin level ≤ 10%, high-risk CKD, and a stable dose of renin–angiotensin system (RAS) inhibitors. Kidney disease was defined as an estimated glomerular filtration rate (eGFR) of 25–75 mL/min/1.73 m2, with a urinary albumin-to-creatinine ratio of >300 and <5000 if the eGFR was ≥50 mL/min/1.73 m2 or a urinary albumin-to-creatinine ratio of >100 and <5000 for eGFR ranging between 25 and 50 mL/min/1.73 m2. The primary outcome was major kidney disease events, a composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL/min/1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes. Confirmatory secondary outcomes included eGFR slope (i.e. the annual rate of change in eGFR from randomization to the end of the trial); major cardiovascular events (a composite of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes); and death from any cause. The mean age of participants was 67 years (30% women, 66% White), with a mean glycated haemoglobin level of 8%, a mean body mass index (BMI) of 32, and a duration of T2D longer than 15 years in more than half. The mean eGFR was 47 mL/min/1.73 m2 (11% of patients had eGFR < 30 mL/min/1.73 m2) and the median urinary albumin-to-creatinine ratio was 568. Up to 23% of patients had a previous cardiovascular event (myocardial infarction or stroke). Only 16% of patients received sodium-glucose co-transporter (SGLT)-2 inhibitors, and more than 90% were treated with RAS inhibitors. Two-thirds of participants were estimated to be at very high risk for kidney disease progression, kidney failure, cardiovascular events, or death.2 Based on a pre-specified interim analysis, the trial was stopped prematurely on the grounds of efficacy. At completion, the median participant follow-up was 3.4 years, with vital status known for 99% of participants and an average of 89% adherence to study treatment during the study period. Primary outcome events occurred less frequently in the semaglutide group [331 events vs. 410; hazard ratio (HR), 0.76; 95% confidence interval (CI), 0.66–0.88; P = .0003; number needed to treat, 59 per year of treatment]. Lower risk with semaglutide was also observed for a composite of the kidney-specific components of the primary outcome (HR, 0.79; 95% CI, 0.66–0.94), as well as for death from cardiovascular causes (HR, 0.71; 95% CI, 0.56–0.89). Results were consistent across pre-specified subgroups, including eGFR and glycated haemoglobin range, BMI, medications, race, and previous cardiovascular events. The mean annual slope of the eGFR was less steep in the semaglutide group (between-group difference, 1.16 mL/min/1.73 m2; 95% CI, 0.86–1.47; P < .001). The risk of major cardiovascular events was 18% lower in the semaglutide group than in the placebo group (212 vs. 254 events; HR, 0.82; 95% CI, 0.68–0.98; P = .029), and the risk of death from any cause was 20% lower (227 vs. 279 events; HR, 0.80; 95% CI, 0.67–0.95; P = .01). The mean change in body weight and glycated haemoglobin level from baseline to Week 104 was greater in the semaglutide group than in the placebo group, by 4.1 kg and 0.8%, respectively. Serious adverse events were reported in fewer participants in the semaglutide group than in the placebo group (50% vs. 54%), mostly driven by less serious infections and less serious cardiovascular events. Gastrointestinal symptoms represented the main cause of semaglutide permanent discontinuation. Chronic kidney disease affects more than 800 million people worldwide, especially in low- and middle-income countries, and is particularly prevalent among individuals with T2D.3 Due to an increased risk of kidney failure, cardiovascular events and death, CKD is still associated with significantly high morbidity and mortality, with the consequence of a huge social and economic burden, and the critical need for more effective prevention and treatment strategies. This is particularly true in subjects with T2D and obesity, in whom mechanisms underlying the development and progression of CKD, such as glomerular hyperfiltration, low-grade inflammation, oxidative stress, increased tubular sodium reabsorption, and activation of the RAS, are amplified.4 Renin–angiotensin system inhibitors and SGLT-2 inhibitors showed beneficial effects on kidney function and cardiovascular events and currently represent established treatments for CKD and T2D.5–8 In spite of the positive effects of these therapies, patients with CKD and T2D remain at high risk of progression of renal failure, major cardiovascular events, and death. Recent evidence suggests a potential protective effect of GLP-1 receptor agonists in this setting. Most of the data supporting this hypothesis, however, have been based on the analysis of secondary or post hoc renal endpoints, in studies performed in patients with and without CKD, where renal outcomes were derived from exploratory analyses.9 A recent study examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial population, showing a clinical benefit (22% reduction in the pre-specified main kidney endpoint) in high-risk individuals with overweight/obesity and without diabetes.10 The FLOW trial is the first randomized trial specifically designed to investigate the effect of semaglutide on renal outcomes in the CKD population.1 This is one of the major strengths of the study, along with the large sample size, the relatively long follow-up, and the high rate of treatment adherence with only modest treatment discontinuation. Although the subjects enrolled were not selected based on body weight or BMI, the study population largely consisted of an overweight/obese cohort (mean BMI 32), although the beneficial effects of semaglutide appeared to be independent of the limited weight loss or the modest effect on the glycaemic profile. These considerations underscore the potential contributory role of other mechanisms of action, which could also at least partly justify the observed reduction in major cardiovascular events and mortality and thus deserve further investigation. Although the benefits of semaglutide were obtained in a very well-treated population, receiving stable maximal doses of RAS inhibitors, the number of patients taking SGLT2 inhibitors was modest and the semaglutide effect size was highly statistically uncertain. Thus, this trial cannot clarify whether semaglutide adds an appreciable benefit in patients who are already on SGLT2 inhibitors. Similarly, the non-steroidal antagonist of mineralocorticoids, finerenone, which is reported to exert sizeable renal protection in CKD/T2D patients, was not included in the therapy of the patients studied.11,12 Besides these relevant limitations, the large prevalence of White individuals compared with other ethnicities strongly affects the generalizability of the results, particularly for the Black population in which CKD and T2D are frequent. Finally, the study was not designed and powered to assess the cardiovascular effects of semaglutide; thus, it cannot be considered conclusive in this regard, despite a very encouraging and statistically significant effect on major cardiovascular events. In conclusion, the ground-breaking results of the FLOW trial, showing a clear reduction in the risk of kidney disease-related events, support the use of semaglutide in patients with CKD and T2D. Further studies are needed to define the effects obtained in association or in alternative to other effective drug classes, such as SGLT2 inhibitors and finerenone, to assess the potential cardiovascular benefits and to extend the representativity of all ethnic groups and non-obese subjects. D.P. received speaker’s fees from Daiichi Sankyo, outside the submitted work. M.V. reports personal fees for speaker bureau and/or consulting in Advisory Boards from Astra Zeneca, Bayer, GSK, Menarini Int, Novartis Pharma, Novo Nordisk, Pfizer, Sanofi Pasteur, and Servier. M.V. is supported by a research grant from Italian Ministry of Health (‘Ricerca corrente’).